食管疾病2023，Vol.5Issue(4)：269-274,6.DOI:10.15926/j.cnki.issn2096-7381.2023.04.006
信迪利单抗联合新辅助化疗在局部晚期食管癌治疗中的疗效分析
Efficacy Analysis of Sintilimab Combined with Neoadjuvant Chemotherapy in Treatment of Locally Advanced Esophageal Cancer
摘要
Abstract
Objective To study the clinical efficacy of sintilimab combined with albumin-bound paclitaxel+nedaplatin in preoperative neoadjuvant treatment of locally advanced esophageal cancer.Methods Retrospective analysis was used on the clinical data of 82 patients who received preoperative neoadjuvant treatment and then underwent radical resection of esophageal cancer in our hospital from January 2019 to De-cember 2021.According to the different treatment plans,patients were divided into group A with 40 cases and group B with 42 cases.Before operation,group A patients received neoadjuvant chemotherapy with sintilimab immunotherapy combined with albumin bound paclitaxel+nedaplatin while group B patients received only al-bumin bound paclitaxel+nedaplatin neoadjuvant chemotherapy.Both groups underwent thoracoscopic esophageal cancer radical surgery after two cycles of treatment.The basic information,adverse reactions to chemotherapy during neoadjuvant therapy,perioperative indicators,and postoperative pathological response of the two groups were compared and evaluated.Re-sults There was no statistically significant difference in the basic data between the two groups of patients.There was no statistically significant difference in the incidence of adverse reactions be-tween the two groups.The partial response rate of group A patients was higher than that of group B,the disease progression rate is lower than that of group B;the objective response rate(ORR)and disease control rate(DCR)were better than those in group B(P＜0.05).There was no statistically significant difference in the complete remission rate and disease stability rate between the two groups of patients.There was no statistically significant difference in perioperative indicators,postoperative anastomotic fistula,and RO resection rate between the two groups of patients.The major patholog-ic response(MPR)rate of postoperative pathological reaction evaluation in group A was better than that in group B(P＜0.05).There was no statistically significant difference in pathologic complete response(pCR)rate and no response between the two group.Conclusion The combination of Sintilimab and albumin bound paclitaxel and nedaplatin is superior to chemotherapy with albumin bound paclitaxel and nedaplatin a-lone,without increasing significant chemotherapy adverse reactions.Moreover,the patient's tolerance is good,improving the objective response rate,disease control rate,and the effectiveness of surgical treatment.关键词
信迪利单抗/新辅助化疗/食管癌/局部晚期Key words
sintilimab/neoadjuvant chemotherapy/esophageal cancer/locally advanced分类
医药卫生引用本文复制引用
李春霖,刘迪,甘绍印,朱德奇,李宾,王永连..信迪利单抗联合新辅助化疗在局部晚期食管癌治疗中的疗效分析[J].食管疾病,2023,5(4):269-274,6.基金项目
新乡医学院第一附属医院青年基金项目(QN-2020-B05) （QN-2020-B05）
